331 related articles for article (PubMed ID: 25031337)
21. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
22. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
Kramer VG; Schader SM; Oliveira M; Colby-Germinario SP; Donahue DA; Singhroy DN; Tressler R; Sloan RD; Wainberg MA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4154-60. PubMed ID: 22615275
[TBL] [Abstract][Full Text] [Related]
23. A high throughput Cre-lox activated viral membrane fusion assay identifies pharmacological inhibitors of HIV entry.
Esposito AM; Cheung P; Swartz TH; Li H; Tsibane T; Durham ND; Basler CF; Felsenfeld DP; Chen BK
Virology; 2016 Mar; 490():6-16. PubMed ID: 26803470
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 requires Arf6-mediated membrane dynamics to efficiently enter and infect T lymphocytes.
García-Expósito L; Barroso-González J; Puigdomènech I; Machado JD; Blanco J; Valenzuela-Fernández A
Mol Biol Cell; 2011 Apr; 22(8):1148-66. PubMed ID: 21346189
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 Entry and Membrane Fusion Inhibitors.
Xiao T; Cai Y; Chen B
Viruses; 2021 Apr; 13(5):. PubMed ID: 33922579
[TBL] [Abstract][Full Text] [Related]
26. Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection.
Kimpel J; Braun SE; Qiu G; Wong FE; Conolle M; Schmitz JE; Brendel C; Humeau LM; Dropulic B; Rossi JJ; Berger A; von Laer D; Johnson RP
PLoS One; 2010 Aug; 5(8):e12357. PubMed ID: 20808813
[TBL] [Abstract][Full Text] [Related]
27. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Platt EJ; Durnin JP; Kabat D
J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
[TBL] [Abstract][Full Text] [Related]
28. In vitro activities of candidate microbicides against cell-associated HIV.
Selhorst P; Grupping K; Bourlet T; Delézay O; Ariën KK; Vanham G
Antimicrob Agents Chemother; 2012 Feb; 56(2):805-15. PubMed ID: 22083472
[TBL] [Abstract][Full Text] [Related]
29. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
Panos G; Watson DC
Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
[TBL] [Abstract][Full Text] [Related]
30. Differential regulation of CXCR4 and CCR5 expression by interleukin (IL)-4 and IL-13 is associated with inhibition of chemotaxis and human immunodeficiency Virus (HIV) type 1 replication but not HIV entry into human monocytes.
Creery D; Weiss W; Graziani-Bowering G; Kumar R; Aziz Z; Angel JB; Kumar A
Viral Immunol; 2006; 19(3):409-23. PubMed ID: 16987060
[TBL] [Abstract][Full Text] [Related]
31. Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors.
Wu CH; Wang CJ; Chang CP; Cheng YC; Song JS; Jan JJ; Chou MC; Ke YY; Ma J; Wong YC; Hsieh TC; Tien YC; Gullen EA; Lo CF; Cheng CY; Liu YW; Sadani AA; Tsai CH; Hsieh HP; Tsou LK; Shia KS
J Med Chem; 2015 Feb; 58(3):1452-65. PubMed ID: 25584630
[TBL] [Abstract][Full Text] [Related]
32. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains.
Lu L; Pan C; Li Y; Lu H; He W; Jiang S
Retrovirology; 2012 Dec; 9():104. PubMed ID: 23217195
[TBL] [Abstract][Full Text] [Related]
33. A potential in vitro and in vivo anti-HIV drug screening system for Chinese herbal medicines.
Feng L; Wang L; Ma YY; Li M; Zhao GQ
Phytother Res; 2012 Jun; 26(6):899-907. PubMed ID: 22852142
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of HIV-1 entry by the tricyclic coumarin GUT-70 through the modification of membrane fluidity.
Matsuda K; Hattori S; Kariya R; Komizu Y; Kudo E; Goto H; Taura M; Ueoka R; Kimura S; Okada S
Biochem Biophys Res Commun; 2015 Feb; 457(3):288-94. PubMed ID: 25576356
[TBL] [Abstract][Full Text] [Related]
35. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
Lin G; Bertolotti-Ciarlet A; Haggarty B; Romano J; Nolan KM; Leslie GJ; Jordan AP; Huang CC; Kwong PD; Doms RW; Hoxie JA
J Virol; 2007 Sep; 81(18):9956-66. PubMed ID: 17609282
[TBL] [Abstract][Full Text] [Related]
36. HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4.
Smith EB; Ogert RA; Pechter D; Villafania A; Abbondanzo SJ; Lin K; Rivera-Gines A; Rebsch-Mastykarz C; Monsma FJ
J Biomol Screen; 2014 Jan; 19(1):108-18. PubMed ID: 23989454
[TBL] [Abstract][Full Text] [Related]
37. Purinergic receptors are required for HIV-1 infection of primary human macrophages.
Hazleton JE; Berman JW; Eugenin EA
J Immunol; 2012 May; 188(9):4488-95. PubMed ID: 22450808
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.
Mostashari Rad T; Saghaie L; Fassihi A
Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572
[TBL] [Abstract][Full Text] [Related]
39. Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1.
Lee S; Lapham CK; Chen H; King L; Manischewitz J; Romantseva T; Mostowski H; Stantchev TS; Broder CC; Golding H
J Virol; 2000 Jun; 74(11):5016-23. PubMed ID: 10799575
[TBL] [Abstract][Full Text] [Related]
40. Specific reactions between purified HIV-1 particles and CD4+ cell membrane fragments in a cell-free system of virus fusion or entry.
Harada T; Tatsumi M; Takahashi H; Sata T; Kurata T; Kojima A
Microbes Infect; 2004 Apr; 6(5):421-8. PubMed ID: 15109956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
